Pretreatment tumor sampling and prognostic factors in patients with soft-tissue sarcoma of the head and neck

Eur Arch Otorhinolaryngol. 2022 Jun;279(6):3147-3155. doi: 10.1007/s00405-021-07162-0. Epub 2021 Nov 12.

Abstract

Background: Insufficient preoperative work-up and consequent intralesional or marginal resection of soft-tissue sarcomas of the head and neck (STSHNs) is common.

Methods: This retrospective cohort study comprised 63 patients with STSHN treated at the Helsinki University Hospital between 2005 and 2017. We assessed the effect of pretreatment tumor sampling on surgical margin status and need for supplemental surgery, as well as prognostic factors and survival.

Results: The lack of representative pretreatment biopsy specimen was associated with unfavorable margin status. Primary surgery at a non-academic center was associated with need for supplemental surgery. The 3-year overall survival (OS) was 68%, disease-specific survival (DSS) 71%, and recurrence-free survival (RFS) 61%. Higher tumor grade and primary tumor size over 5 cm were associated with reduced DSS.

Conclusions: Diagnosis and management of STSHNs should be centralized to experienced academic centers. Decision-making between needle biopsy, open biopsy, or upfront radical surgery depends on tumor location and size.

Keywords: Head and neck sarcoma; Pretreatment work-up; Prognostic factors; Single-center experience; Survival.

MeSH terms

  • Biopsy
  • Humans
  • Neoplasm Recurrence, Local / therapy
  • Prognosis
  • Retrospective Studies
  • Sarcoma* / diagnosis
  • Sarcoma* / pathology
  • Sarcoma* / surgery
  • Soft Tissue Neoplasms* / pathology